USPTO serial 99064085
TRIFECTA CELL INFUSION
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- GAGLIARDI, JEANINE
- Law office
- TMO LAW OFFICE 120
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with TRIFECTA CELL INFUSION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael J. McCue
Michael J. McCue Womble Bond Dickinson (US) LLP8488 Rozita Lee Avenue, Suite 400Las Vegas, NV 89113United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations and substances for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention and treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical preparations and substances containing autologous or allogeneic cells for the treatment of human diseases and animal diseases in the nature of cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases and infectious diseases; biologic in the nature of pharmaceutical preparations for the treatment of autoimmune diseases, infectious diseases, and cancer, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, antibodies, fusion proteins, peptide and cytokine biologics, and natural killer cell derived preparations for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures being biological preparations for medical purposes and reagents for medical use and also including printed instructions, for use in the treatment and prevention of bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, and cancer for clinical, medicinal, therapeutic and veterinary purposes; all of the aforementioned excluding preparations and substances used in connection with implant material | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 30, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 30, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 1, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 1, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 1, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 17, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 17, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 17, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 27, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 27, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 7, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 5, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 3, 2025 | NWAP | NEW APPLICATION ENTERED | — |